06872.HK
Tennor Therap-b
HKSE · Healthcare · Biotechnology · CN
HKD 168.00
−3.34%Income statement
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Expenses | |||
| R&D Expense | 71.9M | 69.8M | 108.4M |
| SG&A Expense | 5.7M | 3.5M | 4.5M |
| General & Admin Expense | 5.7M | 3.5M | 4.5M |
| Selling & Marketing Expense | 629.0K | 430.0K | 404.0K |
| Other Expenses | 41.1M | 4.7M | 9.6M |
| Total Operating Expenses | 118.7M | 78.0M | 122.5M |
| Cost and Expenses | 118.7M | 78.0M | 122.5M |
| Operating Income (EBIT) | (118.7M) | (78.0M) | (122.5M) |
| Non-Operating | |||
| Interest Income | 664.0K | 250.0K | 474.0K |
| Interest Expense | 1.5M | 1.9M | 2.3M |
| Net Interest Income | (818.0K) | (1.6M) | (1.9M) |
| Other Non-Op Income/Expense | (34.6M) | (67.9M) | (69.4M) |
| Non-Operating Income (excl Interest) | 33.1M | 66.0M | 67.0M |
| EBT (Pre-Tax Income) | (153.2M) | (145.9M) | (191.8M) |
| Income Tax Expense | — | — | — |
| Bottom Line | |||
| Net Income | (153.2M) | (145.9M) | (191.8M) |
| Earnings from Cont. Ops | (153.2M) | (145.9M) | (191.8M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (153.2M) | (145.9M) | (191.8M) |
| Per Share | |||
| Basic EPS | (HK$2.96) | (HK$2.82) | (HK$3.71) |
| Diluted EPS | (HK$2.96) | (HK$2.82) | (HK$3.71) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||
| Basic Shares Outstanding | 51.8M | 51.8M | 51.8M |
| Diluted Shares Outstanding | 51.8M | 51.8M | 51.8M |
| Profitability Metrics | |||
| EBITDA | (150.2M) | (141.3M) | (186.6M) |
| D&A | 1.6M | 2.7M | 2.9M |
| EBIT | (151.8M) | (144.0M) | (189.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025